Mirrored: 8th of June 2011, 08:19 Original: www.thepharmaletter.com Views: 141 Settings: Loading the mirror...
Sign up for a free trial now * Login * Subscribe * Take a FREE Trial * About Us * Contact us * RSS 08 June 2011 Search _____________________ [ search ] The Pharma Letter * Home * 7 Day Premium Trial * Pharmaceuticals * Biotechnology * Generics * Events * Companies * Drugs * Subscribe Keywords: eu, clears, orion/novartis, stalevo, european, union-wide, marketing EU clears Orion/Novartis' Stalevo Article | 3 November 2003 * Print This * A European Union-wide Marketing Authorization has been received byFinland's Orion for its Parkinson's disease treatment Stalevo (a combination of carbidopa, levodopa and entacapone) which, the company claims, is the first new PD therapy in three years and the first new form of levodopa in more than a decade. Enjoying this article? To continue reading you need to login or subscribe. Subscribe now for unlimited access to all articles Subscriptions are -L-60 per month, pay as you go. Find out more details. Already a subscriber? Click here to log in Related Companies Novartis Go to company listing Related Drugs Carbidopa, Levodopa and Entacapone Stalevo Dopar Levodopa Comtan Go to drug listing Related Articles New wave of drugs offer hope in treatment of colon cancer 3 November 2003 New NICE guidance on NHS use of Gleevec and CAD stents in England/Wales 3 November 2003 Avant losses widened in third quarter 3 November 2003 Avera licenses depression compound from Novartis 3 November 2003 Stock Commentary - Europe 3 November 2003 Latest Articles Pharma majors slash vaccine prices to poorest countries 7 June 2011 Unprecedented survival results for B-MS Yervoy and Roche*s vemurafenib in melanoma discussed at ASCO 7 June 2011 More highlights from ASCO 7 June 2011 Sanofi presents benefits of semuloparin; Zaltrap improves colorectal cancer survival 7 June 2011 EPHA calls for transparency of European medicines pricing 7 June 2011 More latest M&A 2010 * Hot Topics * Most Read * Johnson & Johnson faces $327 million penalty over Risperdal marketing * Pharma majors slash vaccine prices to poorest countries * Blow for Orexigen as regulatory demands see firm put obesity drug Contrave on hold * Unprecedented survival results for B-MS Yervoy and Roche*s vemurafenib in melanoma discussed at ASCO * ASCO highlights include GSK*s pazopanib, Novartis* INC424 and Glivec, B-MS/Otsuka*s Sprycel * Johnson & Johnson faces $327 million penalty over Risperdal marketing * Pharma majors slash vaccine prices to poorest countries * Blow for Orexigen as regulatory demands see firm put obesity drug Contrave on hold * Unprecedented survival results for B-MS Yervoy and Roche*s vemurafenib in melanoma discussed at ASCO * ASCO highlights include GSK*s pazopanib, Novartis* INC424 and Glivec, B-MS/Otsuka*s Sprycel 30 Day Premium Trial - Thin Twitter Right banner RSS Events (c) 2011 thepharmaletter.com * Home * RSS * About Us * Subscribe * Terms and Conditions * Article Archive Site powered by WORKSsitebuilder CMS